One drawback of the approach of Kitzman et al. 7 is that it requires stitching together phased contigs, albeit rather large ones. This may result in switching errors, where chromosomal segments are accurately haplotyped but misrepresent complete chromosomes. Such errors can occur once or many times over different chromosomes. These concerns are eliminated in the approach developed by Fan et al. 6 , which resolves phase directly by isolating individual copies of each chromosome in a single cell with a microfluidic device. Thus, there is no need to assemble contigs. After isolation of single chromosomes, a haploid mixture of clones derived from either the maternal or paternal DNA can be genotyped using standard singlenucleotide polymorphism arrays or shotgun sequenced to generate haplotypes spanning entire chromosomes (Fig. 1c) .
Fan et al. 6 validate their approach by haplotyping the genomes of a mother-father-child trio from the HapMap project. The experimentally determined haplotypes are highly concordant (99.8%) with previously calculated haplotypes inferred using family and population information, demonstrating the accuracy of the approach. The authors also demonstrate the potential of their method for clinical diagnostics by haplotyping a fourth individual, P0, whose genome has already been sequenced, at the highly polymorphic HLA locus. Phase information for this genomic region is very important for matching transplanted donor organs with a potential host. Although the approach taken by Fan et al. 6 is direct and the most optimal for phasing, the need for sophisticated microfluidic devices and sequencing . . . . . . 7 exploit large-insert fosmid clone libraries that allow sequencing reads derived from a single chromosomal homolog to be associated with each other. Cloning and sequencing is multiplexed, enabling efficient construction of contigs that span large genomic regions. Although this approach may be easier to implement in most sequencing laboratories, it is less robust than the approach of Fan et al. 6 owing to the need for assembly. (c) Fan et al. 6 use a microfluidic device to separate and amplify homologous chromosomes during metaphase in single cells, enabling the individual chromosomes to be sequenced and nearly perfectly phased.
Unphased genetic variants
technologies able to handle individual chromosomes may delay its routine use. The work of Fan et al. 6 and Kitzman et al. 7 highlight the obvious, yet often overlooked, diploid nature of the human genome and expose the incompleteness of available individual genome sequences that do not phase genetic variants. Going forward, discussions of individual human genomes should refer either to a single maternally or paternally derived haplotypic complement of DNA or to the two genomes that each person possesses. This simple change in language should help emphasize the importance of studies that account for the phase information that is the hallmark of the human genome.
injection of naked DNA into the pronuclei of mouse zygotes. Until now, however, pronuclear injection has allowed insertion of exogenous DNA only at random sites in the genome, and site-specific engineering has proved extremely difficult. In this issue, Cui and colleagues 1 have finally overcome this barrier, making use of zinc-finger nucleases (ZFNs) to stimulate targeted integration of transgenes by homologous recombination in mouse and rat zygotes. This technology will dramatically alter the speed Mammalian oocytes and zygotes are extraordinarily resilient receptacles that provide a conduit from designs etched in laboratory notebooks to living animals. The first transgenic mammals were generated three decades ago by
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Evidence that mouse pro-nuclei are endowed with the machinery to support homologous recombination emerged more than 20 years ago, but the efficiencies were too low to be practically useful 2 . Instead, the technology to manipulate the mouse genome has relied on embryonic stem (ES) cells, which are extraordinarily receptive to homologous recombination. Mouse ES cells with targeted mutations are now available for >12,000 genes; these cells have thus become the genetic repository for the mouse. Unfortunately, the link between cultured ES cells and the production of mutant animals could not be readily established in other species. ES cell lines isolated from species other than the mouse rarely exhibit germline colonization, although recent success has been reported in the rat 3 .
The lack of authentic ES cells held back targeted genome manipulation in most mammalian species for many years. This barrier was eventually overcome by exploiting the remarkable ability of a mammalian oocyte to reprogram a somatic cell nucleus, effectively converting it to a zygotic genome ( Fig. 1) . By performing gene targeting in cultured somatic cells and then using the engineered cells for nuclear transfer, it became possible to manipulate endogenous genes in several mammalian species 4 . Despite these successes, the technical difficulties have been substantial because of the low efficiencies of both gene targeting in somatic cells and subsequent reprogramming of their nuclei.
The research reported by Cui et al. 1 provides for the first time a route to directly manipulate the rat genome, an approach that bypasses the requirement for germline competent ES cells or somatic cell nuclear transfer (Fig. 1) . The major difficulty in achieving gene targeting with naked DNA injected into pro-nuclei is the very low efficiency of targeted rather than random integration 2 . Gene targeting is stimulated by several orders of magnitude in somatic cells by provision of a double-strand break in the genome 5 . Cleaving the mammalian genome at a defined site was not possible before the development of ZFNs, modular proteins that couple zincfinger DNA-binding domains to the nuclease domain of the restriction endonuclease FokI 6 . They function as homo-or heterodimers, cleaving DNA between the two binding sites (Fig. 1) , and in principle can be designed to target any unique site in complex genomes.
After the initial demonstration of sequencespecific cleavage of the Drosophila melanogaster genome 7 , ZFNs were shown to stimulate targeted integration of a template sequence by means of homologous recombination in fruitflies, plants and human cells. Cui et al. 1 and a recent report 8 both demonstrate that co-injection of a pair of ZFN mRNAs with a targeting vector into pro-nuclei stimulates the frequency of gene targeting in mice to workable levels of 2-20% ( Fig. 1) . Cui et al. 1 extend this approach to the rat. Interestingly, live-born founder animals obtained from these experiments 1,8 are mosaics that carry several different mutant alleles with deletions at the target locus, as well as correctly targeted alleles and unmodified wild-type alleles. Deletions are expected products following nonhomologous end-joining of cleaved DNA in the absence of targeting and have been described previously following expression of ZFNs in zygotes 9 . The transmission of multiple different mutant alleles from the same founder reflects germline mosaicism caused by expression and cleavage activity of ZFNs after DNA replication in maternal and/ or paternal pro-nuclei. The ability to simultaneously generate a spectrum of mutations can be advantageous for genetic purposes. Figure 1 Three principal routes to achieve targeted genome modifications in the rat and other mammalian species. ES cell, embryonic stem cell; HR, homologous recombination; ZFN, zinc-finger nuclease; DSB, double-strand break; NHEJ, non-homologous end joining.
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Despite these advances, several questions about ZFN-stimulated pronuclear targeting remain to be addressed. Molecular biologists are familiar with unwanted off-target activity of restriction enzymes. To what extent do ZFNs cleave other sites in the genome? The comparatively small size of deletions generated at illegitimate sites suggests that offtarget cleavages will be hard to trace. Does the physical damage of the host genome observed in many transgenic animals generated by pronuclear injection occur in this setting, too? The importance of the answers to these questions will undoubtedly depend on the frequency and type of unwanted events, their linkages to the desired genomic alterations and the context in which the technology is applied.
The mutant alleles generated using conventional gene targeting technology in mouse ES cells have become increasingly sophisticated over the past two decades. The repertoire of genetic alterations that can be achieved by ZFN-stimulated pronuclear targeting is fertile ground for exploration. Although mutant rats have recently been produced using rat ES cell technology 10 (Fig. 1) , ZFN targeting applied directly to the zygote (Fig. 1) presents considerable advantages. Pronuclear injection of nucleic acids is well established, widely practiced and applicable to any strain. Moreover, transmission of the engineered allele from founder rats is readily achieved. Provided that ZFNs with the appropriate specificity can be generated, the community of rat researchers can look forward to rats with a myriad of defined genome modifications.
This technology will also find applications in a multitude of other species, which hitherto have required somatic cell reprogramming to achieve directed modifications of their genomes. Although vector-chromosome gene targeting has yet to be demonstrated in the pro-nuclei of farm animal zygotes, this is likely to be possible. ZFNs have been shown to stimulate gene targeting in a variety of species and can therefore be used in combination with somatic nuclear transfer, removing a bottleneck in achieving directed modification by this route. The promise of this technology will stimulate numerous applications, but the terms, conditions and costs associated with commercially provided ZFNs can be prohibitive and may limit their potential. safer because internal regulatory sequences can be designed to be less mutagenic, and their intrinsic integration mechanisms may be less prone to target sensitive chromosomal regions. Even so, there remains a finite risk of mutagenesis for all semi-randomly or randomly integrating vectors, as recently demonstrated in a clinical trial for β-thalassemia 4 . Strategies to mediate safe integration-and, ultimately, gene correction-are therefore of considerable interest.
Successful treatment of devastating diseases of the immune system has been accomplished using high-efficiency gene transfer into hematopoietic stem and early progenitor cells with retroviral vectors. However, as emphasized by the occurrence of leukemia in several otherwise successful clinical trials, the integration of gamma-retroviral vectors containing powerful enhancers in the viral long terminal repeats carries a risk of insertional mutagenesis. In this issue, Papapetrou et al. 1 propose to reduce this risk by bioinformatic screening of randomly transduced cells to identify clones whose integration sites are located far from potentially dangerous regions of the genome. They demonstrate that screening insertion sites in hematopoietic cells derived from induced pluripotent stem (iPS) cells can readily identify apparently safe integrations that permit transgene expression at clinically relevant levels.
As seen in recent clinical trials for X-linked severe combined immunodeficiency, chronic granulomatous disease and Wiskott-Aldrich syndrome, activation of oncogenes by integrating viral vectors appears to provide a 'first hit' that in some cases is associated with secondary genetic events and ultimately full leukemic transformation. Although it is the potent and relatively indiscriminate properties of the gamma-retroviral long terminal repeats that ultimately do the damage, recent detailed mapping of integration sites also suggests that there may be a tethering between long terminal repeat sequences and active gene regulatory regions 2, 3 . Retroviral vectors of all classes that lack long terminal repeats are likely to be Out of harm's way 
